Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
Summary
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...
Description from Medpagetoday.
Who is covering this
-
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...
Related stories
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
26 sourcesvia BBC NewsTruth score 918
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
7 sourcesvia The HinduTruth score 731
FDA scientists opposed Trump administration’s move to ease peptide access
4 sourcesvia The GuardianTruth score 66
Blood pressure medication recalled nationwide
4 sourcesvia USA TODAYTruth score 671
Patanjali ghee among Rs 9 crore food stock seized in Maharashtra FDA crackdown
3 sourcesvia India TodayTruth score 54
Trump administration says biggest changes coming to infant formula in nearly 30 years
2 sourcesvia ABC News (US)Truth score 533
Comments
Comments need JavaScript.